BRUKER CORPORATION (NASDAQ: BRKR) Q1 2026 Earnings Presentation May 6, 2026 Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations Q1 2026 Business Update 3 BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and ...

DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointment of Cenly Chen as Chief Executive Officer and a member of the Company’s Board of Directors. Ms. Chen brings more than two decades of experience scaling enterprise infrastructure and high-performance computing platforms in global markets. She most recently served as Chief Growth Officer, Senior Vic ...

Public drug coverage now provides eligible adults access to CRYSVITA, the only approved treatment for X-linked hypophosphatemia (XLH), a lifelong progressive disease TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Canada, a wholly owned subsidiary of Kyowa Kirin Inc., is pleased to announce that CRYSVITA® (burosumab injection) is now publicly funded for eligible adults living with X-linked hypophosphatemia in Ontario, British Columbia, Saskatchewan, and Alberta, as well as through the federal Non-Insu ...

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical and scientific conferences in May and June 2026, including new clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting. IN8bio will also host a Research and Development (R&D) Day on May 21, ...

Q1 2026 EARNINGS REVIEW CONFERENCE CALL // May 6, 2026 NYSE: PAAS | TSX: PAAS 1 CAUTIONARY NOTE Non-GAAP Measures This presentation of Pan American Silver Corp. and its subsidiaries (collectively, "Pan American", "Pan American Silver", the "Company", "we" or "our") refers to various non-GAAP measures, such as "AISC", "adjusted earnings", "attributable revenue", "attributable cash flow from operations", "attributable free cash flow", "basic adjusted earnings per share", "total debt", and "working capital". T ...

业绩总结 - 第三季度调整后每股收益为0.96美元，同比增长6%[7] - 第三季度净销售额为59.14亿美元，年初至今净销售额为171.08亿美元[9] - 第三季度调整后EBITDA为8.92亿美元，调整后EBIT为6.87亿美元，分别占净销售额的15.1%和11.6%[9] - 核心业务的净销售额约为52亿美元，整体公司的净销售额为59.14亿美元[19] - 核心业务的EBIT利润率约为12.3%，整体公司的EBIT利润率为11.6%[19] 用户数据 - 收购贡献了29%的总增长，金额为6.95亿美元，调整后的息税前利润（Adjusted EBIT）增长32%，增加了1.09亿美元[25] - 全球刚性包装解决方案的净销售额同比增长187%，达到16.64亿美元，调整后的息税前利润同比增长294%，达到2.76亿美元[26][27] - 2026财年第一季度，全球灵活包装解决方案的净销售额为3,250百万美元，同比增长29%[67] - 2026财年第一季度，全球刚性包装解决方案的净销售额为2,664百万美元，同比增长77%[67] 未来展望 - 2026财年调整后每股收益预期为3.98至4.03美元，年增长约12%[7] - 2026财年自由现金流预期为15亿至16亿美元[7] - 预计2026财年末的杠杆率为3.4至3.5倍，之前预期为3.1至3.2倍[40] - 预计2026财年的调整后每股收益（Adjusted EPS）在3.98至4.03美元之间，同比增长约12%[40] - 预计2026财年的自由现金流将受到中东冲突的暂时性影响，但对调整后的每股收益没有实质性影响[39] 新产品和新技术研发 - 第三季度实现协同效应7700万美元，年初至今协同效应达到1.7亿美元，预计2026财年的协同效应将达到2.7亿美元[7][14] 市场扩张和并购 - 合并六项业务的交易总值约为5亿美元，已宣布的四项额外资产剥离[7][13] - 公司计划通过六项业务的组合出售实现约5亿美元的交易价值，以优化投资组合[53] 负面信息 - 2026财年自由现金流预计在15亿至16亿美元之间，较原先预期的18亿至19亿美元有所下调[40]

May 6, 2026 First-Quarter 2026 Earnings Update Safe Harbor Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributi ...

May 6, 2026 First Quarter of 2026 Earnings Conference Call and Webcast 1 / 25 Forward-Looking Statements and Non-IFRS Alternative Performance Measures This presentation contains certain forward-looking statements and information relating to Ternium S.A. and its subsidiaries (collectively, "Ternium") that are based on the current beliefs of its management as well as assumptions made by and information currently available to Ternium. Such statements reflect the current views of Ternium with respect to future ...

First Quarter 2026 Earnings Presentation May 6, 2026 Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Terms such as "aim," "anticipate," "believe," "confidence," "contemplate," "continue," "conviction," "could," "drive," "estimate," "expect," "forecast," "fut ...

2026 EARNINGS REPORT Q1 2026 EARNINGS REPORT Enric Asunción Co-Founder & Chief Executive Officer Isabel López Trujillo Chief Financial Officer Michael Wilhelm Investor Relations Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Sect ...